Statement from AfPA Regarding Associated Press Story
“The Associated Press article follows a growing media trend of reporting on patient advocacy groups and their funding, while ignoring the substance of the policy issues they raise and the good work they do on behalf of physicians and patients. AfPA is one among hundreds of patient groups and medical societies who have expressed concerns about how recent proposals from CMS, HHS and the administration impact patients. These proposals represent the biggest changes to the health care system since the implementation of the Affordable Care Act. Patient advocacy organizations like AfPA must share their insights on how these proposals, if enacted, will impact patient care and the physician-patient relationship.
“AfPA receives support from organizations who support the mission of ensuring patients have access to the medicines their physician prescribes, including companies that manufacture medicines. AfPA is fully transparent in all of its IRS filings and takes the extra step of making available on its website a current list of its supporters.
“To elevate the physician voice in health care policy debates, AfPA has assembled a dynamic team of creative, seasoned and hard-working professionals that have extensive experience in advocacy campaigns, policy, communications, and coalition management. In 2018 alone, AfPA and its related groups produced 75 infographics, 14 report cards, 19 policy papers, 109 blog posts, 29 events, 6 podcasts, and 24 videos. This level of work happens because of the talented and hardworking team at AfPA.”
The Department of Health and Human Services (HHS) is pushing a risky experiment that restructures how patients receive care in Medicare Part B. These sweeping changes would cause America’s sickest, most vulnerable patients to suffer a number of negative consequences. The HHS plan would force patients and doctors into a mandatory experiment that would limit patient access to care and treatments, put a middleman between patients and doctors, and impose European-style price fixing on drugs in America, stifling cancer research.
Radio: Listen to AfPA’s Radio Ad
In a storyline reminiscent of holiday favorite “The Grinch,” the Trump administration seems to be using the season of giving to plot the theft of something Americans hold dear – seniors’ Medicare, in this case.
In the News
We are writing on behalf of the Part B Access for Seniors and Physicians (ASP) Coalition, which is committed to advancing life-saving innovation in the U.S. We are greatly concerned about a proposal by the Centers for Medicare & Medicaid Services (CMS) to implement an unprecedented, mandatory experiment affecting Medicare beneficiaries who take Part B-covered drugs. We support efforts to strengthen the United States’ health care system through patient-centered reforms that embrace competition, foster the provider-patient relationship, and value transformation.
Trump Medicare Drug Plan Would Hurt Most Vulnerable Patients
Mercury News, January 2, 2019
PIPC Submits Letter to CMS on Proposed International Pricing Index
PIPC, January 1, 2019
HHS Drug Price Plan Is a Gift to Global ‘Freeloaders’
Real Clear Health, December 27, 2018
Medicare Drug Proposal Will Prevent New Medicines from Coming to Market
The Hill, December 18, 2018
Trump Officials Say Drug Prices Are Inflated. So Are Some of Their Claims on a Solution.
New York Times, December 16, 2018
More Than 300 Groups Seek to Halt CMS’ Plans For Global Drug Pricing Index
AJMC, December 10, 2018
Despite Innovation, Europeans Wait Years for New Cancer Drugs
Reuters, December 3, 2018
Trump’s Misguided Solution to Drug Prices
Galen Institute, December 2, 2018